300601 康泰生物
已收盘 07-17 15:00:00
资讯
新帖
简况
康泰生物最新公告:四价流感疫苗临床试验申请获受理
证券之星 · 07-15 19:49
康泰生物最新公告:四价流感疫苗临床试验申请获受理
康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理
智通财经 · 07-15 19:41
康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理
康泰生物(300601)股东杜伟民质押800万股,占总股本0.72%
证券之星 · 07-05
康泰生物(300601)股东杜伟民质押800万股,占总股本0.72%
6月24日康泰生物发生1笔大宗交易 成交金额256.28万元
证券之星 · 06-24
6月24日康泰生物发生1笔大宗交易 成交金额256.28万元
6月20日康泰生物现1328.43万元大宗交易
证券之星 · 06-20
6月20日康泰生物现1328.43万元大宗交易
康泰生物最新公告:控股股东、实际控制人、持股5%以上股东、部分董事、监事、高级管理人员承诺不减持公司股份
证券之星 · 06-19
康泰生物最新公告:控股股东、实际控制人、持股5%以上股东、部分董事、监事、高级管理人员承诺不减持公司股份
6月19日康泰生物现285.82万元大宗交易
证券之星 · 06-19
6月19日康泰生物现285.82万元大宗交易
6月19日康泰生物创60日新低,嘉实中证疫苗与生物技术ETF基金重仓该股
证券之星 · 06-19
6月19日康泰生物创60日新低,嘉实中证疫苗与生物技术ETF基金重仓该股
康泰生物(300601)6月14日主力资金净卖出2048.69万元
证券之星 · 06-17
康泰生物(300601)6月14日主力资金净卖出2048.69万元
康泰生物(300601)6月13日主力资金净卖出2538.22万元
证券之星 · 06-14
康泰生物(300601)6月13日主力资金净卖出2538.22万元
康泰生物最新公告:2023年年度权益分派10派2元 股权登记日6月13日
证券之星 · 06-05
康泰生物最新公告:2023年年度权益分派10派2元 股权登记日6月13日
康泰生物(300601.SZ)2023年度权益分派:每10股派2元
智通财经 · 06-05
康泰生物(300601.SZ)2023年度权益分派:每10股派2元
海通国际:给予康泰生物增持评级,目标价位24.49元
证券之星 · 06-04
海通国际:给予康泰生物增持评级,目标价位24.49元
5月28日康泰生物发生1笔大宗交易 成交金额1185.99万元
证券之星 · 05-28
5月28日康泰生物发生1笔大宗交易 成交金额1185.99万元
5月24日康泰生物发生2笔大宗交易 成交金额1300.21万元
证券之星 · 05-24
5月24日康泰生物发生2笔大宗交易 成交金额1300.21万元
天风证券:给予康泰生物买入评级
证券之星 · 05-21
天风证券:给予康泰生物买入评级
康泰生物最新公告:四价流感病毒裂解疫苗新增6-35月龄人群临床试验申请获得受理
证券之星 · 05-20
康泰生物最新公告:四价流感病毒裂解疫苗新增6-35月龄人群临床试验申请获得受理
5月20日康泰生物发生1笔大宗交易 成交金额1194万元
证券之星 · 05-20
5月20日康泰生物发生1笔大宗交易 成交金额1194万元
5月15日康泰生物发生3笔大宗交易 成交金额1929.4万元
证券之星 · 05-15
5月15日康泰生物发生3笔大宗交易 成交金额1929.4万元
5月6日康泰生物涨5.20%,嘉实中证疫苗与生物技术ETF基金重仓该股
证券之星 · 05-06
5月6日康泰生物涨5.20%,嘉实中证疫苗与生物技术ETF基金重仓该股
加载更多
公司概况
公司名称:
深圳康泰生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2017-02-07
主营业务:
深圳康泰生物制品股份有限公司主营业务为人用疫苗的研发、生产和销售。公司的主要产品为免疫规划疫苗、非免疫规划疫苗。公司拥有专利70余项,已上市及获批紧急使用的产品10种,在研品种30余项,基本涵盖全球重磅疫苗品种,其中,公司自主研发的用于乙肝疫苗无应答特殊人群的“60µg重组乙型肝炎疫苗(酿酒酵母)”和“双载体13价肺炎球菌多糖结合疫苗”属全球首创。
发行价格:
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":15.48,"timestamp":1721199801000,"preClose":15.19,"halted":0,"volume":9677954,"delay":0,"floatShares":881000000,"shares":1117000000,"eps":0.6356,"marketStatus":"已收盘","marketStatusCode":5,"change":0.29,"latestTime":"07-17 15:00:00","open":15.15,"high":15.66,"low":15.15,"amount":150000000,"amplitude":0.0336,"askPrice":15.48,"askSize":111,"bidPrice":15.47,"bidSize":127,"shortable":0,"etf":0,"ttmEps":0.6356,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721266200000},"adr":0,"adjPreClose":15.19,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":16.71,"lowLimit":13.67,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116916689,"pbRate":1.86,"roa":"--","roe":"0.56%","epsLYR":0.77,"committee":-0.036761,"marketValue":17290000000,"floatMarketCap":13643000000,"peRate":24.354941,"changeRate":0.0191,"turnoverRate":0.011,"status":0},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2451646192","title":"康泰生物最新公告:四价流感疫苗临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2451646192","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451646192?lang=zh_cn&edition=full","pubTime":"2024-07-15 19:49","pubTimestamp":1721044193,"startTime":"0","endTime":"0","summary":"康泰生物公告,公司和兰州百灵生物技术有限公司研发的四价流感病毒裂解疫苗(MDCK细胞)临床试验申请已获国家药品监督管理局受理。该疫苗适用于3周岁及以上人群,用于预防流感病毒引起的流行性感冒。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500027193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK1583","BK1576","BK0239","BK1141","03347","300601","BK0046"],"gpt_icon":0},{"id":"2451664681","title":"康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2451664681","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451664681?lang=zh_cn&edition=full","pubTime":"2024-07-15 19:41","pubTimestamp":1721043672,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康泰生物(300601.SZ)公告,公司今日收到国家药品监督管理局签发的受理通知书,同意受理公司和兰州百灵生物技术有限公司研发的四价流感病毒裂解疫苗(MDCK细胞)的临床试验申请。本次申请临床试验获得受理的四价流感病毒裂解疫苗(MDCK细胞)适用于3周岁及以上人群,可刺激机体产生抗流感病毒的免疫力,用于预防疫苗相关型别的流感病毒引起的流行性感冒。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","03347","159646","BK0239","BK1576","BK1583","300601","BK0201","BK1141"],"gpt_icon":0},{"id":"2449260387","title":"康泰生物(300601)股东杜伟民质押800万股,占总股本0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449260387","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449260387?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:28","pubTimestamp":1720186084,"startTime":"0","endTime":"0","summary":"证券之星消息,康泰生物7月5日公开信息显示,股东杜伟民向国金证券股份有限公司合计质押800.0万股,占总股本0.72%。质押详情见下表:截止本公告日,股东杜伟民已累计质押股份3599.8万股,占其持股总数的12.64%。康泰生物主营业务:人用疫苗的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500048048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","300601","BK0046"],"gpt_icon":0},{"id":"2445301028","title":"6月24日康泰生物发生1笔大宗交易 成交金额256.28万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445301028","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445301028?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:52","pubTimestamp":1719219137,"startTime":"0","endTime":"0","summary":"证券之星消息,6月24日康泰生物发生大宗交易,交易数据如下:大宗交易成交价格15.82元,成交16.2万股,成交金额256.28万元,买方营业部为中信证券股份有限公司上海分公司,卖方营业部为中国国际金融股份有限公司深圳分公司。近三个月该股共发生10笔大宗交易,合计成交4.08万手。该股近期无解禁股上市。截至2024年6月24日收盘,康泰生物报收于15.82元,下跌2.77%,换手率1.0%,成交量8.85万手,成交额1.41亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400022330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0201","BK0046"],"gpt_icon":0},{"id":"2444267118","title":"6月20日康泰生物现1328.43万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2444267118","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444267118?lang=zh_cn&edition=full","pubTime":"2024-06-20 16:40","pubTimestamp":1718872844,"startTime":"0","endTime":"0","summary":"证券之星消息,6月20日康泰生物发生大宗交易,交易数据如下:大宗交易成交价格16.24元,成交81.8万股,成交金额1328.43万元,买方营业部为中信证券股份有限公司上海分公司,卖方营业部为国泰君安证券股份有限公司临海巾山中路证券营业部。近三个月该股共发生9笔大宗交易,合计成交3.92万手。截至2024年6月20日收盘,康泰生物报收于16.24元,上涨0.0%,换手率1.4%,成交量12.33万手,成交额2.03亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000031234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300601","BK0239","BK0201"],"gpt_icon":0},{"id":"2444735124","title":"康泰生物最新公告:控股股东、实际控制人、持股5%以上股东、部分董事、监事、高级管理人员承诺不减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2444735124","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444735124?lang=zh_cn&edition=full","pubTime":"2024-06-19 19:50","pubTimestamp":1718797852,"startTime":"0","endTime":"0","summary":"若本人因未履行上述承诺而获得收入的,所得收入归公司所有。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900039119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","300601"],"gpt_icon":0},{"id":"2444440057","title":"6月19日康泰生物现285.82万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2444440057","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444440057?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:30","pubTimestamp":1718785843,"startTime":"0","endTime":"0","summary":"证券之星消息,6月19日康泰生物发生大宗交易,交易数据如下:大宗交易成交价格16.24元,成交17.6万股,成交金额285.82万元,买方营业部为中信证券股份有限公司上海分公司,卖方营业部为中信证券股份有限公司上海东方路证券营业部。近三个月该股共发生8笔大宗交易,合计成交3.1万手。截至2024年6月19日收盘,康泰生物报收于16.24元,下跌2.05%,换手率0.82%,成交量7.26万手,成交额1.19亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900032829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"gpt_icon":0},{"id":"2444440438","title":"6月19日康泰生物创60日新低,嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2444440438","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444440438?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:20","pubTimestamp":1718785238,"startTime":"0","endTime":"0","summary":"证券之星消息,6月19日康泰生物创60日新低,收盘报16.24元,当日跌2.05%,换手率0.82%,成交量7.26万手,成交额1.19亿元。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为3.67亿元,最新净值0.6101,较上一交易日下跌0.68%,近一年下跌25.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900031987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","159646","BK0239","BK0046","BK0201"],"gpt_icon":0},{"id":"2444891900","title":"康泰生物(300601)6月14日主力资金净卖出2048.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444891900","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444891900?lang=zh_cn&edition=full","pubTime":"2024-06-17 09:21","pubTimestamp":1718587279,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月14日收盘,康泰生物报收于16.73元,下跌2.16%,换手率1.41%,成交量12.44万手,成交额2.09亿元。近5日资金流向一览见下表:康泰生物融资融券信息显示,融资方面,当日融资买入1658.09万元,融资偿还2525.3万元,融资净偿还867.21万元。康泰生物主营业务:人用疫苗的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700001908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","300601","BK0239"],"gpt_icon":0},{"id":"2443666100","title":"康泰生物(300601)6月13日主力资金净卖出2538.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443666100","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443666100?lang=zh_cn&edition=full","pubTime":"2024-06-14 09:22","pubTimestamp":1718328177,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月13日收盘,康泰生物报收于17.3元,下跌2.7%,换手率1.14%,成交量10.02万手,成交额1.75亿元。近5日资金流向一览见下表:康泰生物融资融券信息显示,融资方面,当日融资买入2039.38万元,融资偿还1729.24万元,融资净买入310.14万元。康泰生物主营业务:人用疫苗的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400013236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","300601"],"gpt_icon":0},{"id":"2441027296","title":"康泰生物最新公告:2023年年度权益分派10派2元 股权登记日6月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2441027296","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441027296?lang=zh_cn&edition=full","pubTime":"2024-06-05 22:20","pubTimestamp":1717597249,"startTime":"0","endTime":"0","summary":"康泰生物公告,公司2023年年度权益分派方案为:以2023年年度权益分派实施公告中确定的股权登记日当日的总股本为基数,以未分配利润向全体股东每10股派2元现金红利(含税)。本次权益分派股权登记日为2024年6月13日,除权除息日为2024年6月14日。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500043850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0239","BK0046"],"gpt_icon":0},{"id":"2441273699","title":"康泰生物(300601.SZ)2023年度权益分派:每10股派2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441273699","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441273699?lang=zh_cn&edition=full","pubTime":"2024-06-05 20:39","pubTimestamp":1717591198,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康泰生物(300601.SZ)发布公告,公司2023年年度权益分派方案为:以2023年年度权益分派实施公告中确定的股权登记日当日的总股本为基数,以未分配利润向全体股东每10股派2元现金红利(含税),本次权益分派股权登记日为:2024年6月13日,除权除息日为:2024年6月14日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1131689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0201","BK0046","300601","BK0239"],"gpt_icon":0},{"id":"2440285709","title":"海通国际:给予康泰生物增持评级,目标价位24.49元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440285709","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440285709?lang=zh_cn&edition=full","pubTime":"2024-06-04 18:50","pubTimestamp":1717498240,"startTime":"0","endTime":"0","summary":"海通国际证券集团有限公司Kehan Meng,Wenxin Yu近期对康泰生物进行研究并发布了研究报告《公司季报点评:常规产品实现增长,出海稳步推进》,本报告对康泰生物给出增持评级,认为其目标价位为24.49元,当前股价为17.82元,预期上涨幅度为37.43%。公司人二倍体狂犬疫苗于2023年12月获得批签发证明。最新盈利预测明细如下:该股最近90天内共有11家机构给出评级,买入评级10家,增持评级1家;过去90天内机构目标均价为28.5。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060400035554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0},{"id":"2438344491","title":"5月28日康泰生物发生1笔大宗交易 成交金额1185.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438344491","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438344491?lang=zh_cn&edition=full","pubTime":"2024-05-28 16:42","pubTimestamp":1716885731,"startTime":"0","endTime":"0","summary":"证券之星消息,5月28日康泰生物发生大宗交易,交易数据如下:大宗交易成交价格18.19元,成交65.2万股,成交金额1185.99万元,买方营业部为国泰君安证券股份有限公司深圳华强北路证券营业部,卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生10笔大宗交易,合计成交3.49万手。该股近期无解禁股上市。截至2024年5月28日收盘,康泰生物报收于18.19元,下跌1.46%,换手率0.94%,成交量8.25万手,成交额1.51亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800029891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"gpt_icon":0},{"id":"2437700388","title":"5月24日康泰生物发生2笔大宗交易 成交金额1300.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437700388","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437700388?lang=zh_cn&edition=full","pubTime":"2024-05-24 16:40","pubTimestamp":1716540043,"startTime":"0","endTime":"0","summary":"证券之星消息,5月24日康泰生物发生大宗交易,交易数据如下:近三个月该股共发生9笔大宗交易,合计成交2.84万手。该股近期无解禁股上市。截至2024年5月24日收盘,康泰生物(300601)报收于18.8元,下跌0.69%,换手率0.71%,成交量6.28万手,成交额1.19亿元。该股最近90天内共有10家机构给出评级,买入评级10家;过去90天内机构目标均价为30.66。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400031007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","300601","BK0239"],"gpt_icon":0},{"id":"2437418226","title":"天风证券:给予康泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2437418226","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437418226?lang=zh_cn&edition=full","pubTime":"2024-05-21 18:50","pubTimestamp":1716288641,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松近期对康泰生物进行研究并发布了研究报告《2023年扭亏为盈,人二倍体狂苗销售值得期待》,本报告对康泰生物给出买入评级,当前股价为19.55元。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有9家机构给出评级,买入评级9家;过去90天内机构目标均价为30.66。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100031318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","300601"],"gpt_icon":0},{"id":"2436764961","title":"康泰生物最新公告:四价流感病毒裂解疫苗新增6-35月龄人群临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2436764961","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436764961?lang=zh_cn&edition=full","pubTime":"2024-05-20 18:39","pubTimestamp":1716201597,"startTime":"0","endTime":"0","summary":"康泰生物公告,公司近日收到国家药监局签发的受理通知书,同意受理公司研发的四价流感病毒裂解疫苗新增6—35月龄人群的临床试验申请。公司四价流感病毒裂解疫苗(3岁及以上人群)目前处于Ⅰ、Ⅲ期临床试验阶段,本次公司四价流感病毒裂解疫苗新增6—35月龄人群临床试验申请获得受理。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052000020204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","03347","BK0201","BK1583","BK0046","159646","BK0239","300601"],"gpt_icon":0},{"id":"2436221124","title":"5月20日康泰生物发生1笔大宗交易 成交金额1194万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436221124","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436221124?lang=zh_cn&edition=full","pubTime":"2024-05-20 16:30","pubTimestamp":1716193848,"startTime":"0","endTime":"0","summary":"证券之星消息,5月20日康泰生物发生大宗交易,交易数据如下:大宗交易成交价格19.9元,成交60万股,成交金额1194万元,买方营业部为华泰证券股份有限公司泰州分公司,卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生7笔大宗交易,合计成交2.15万手。该股近期无解禁股上市。截至2024年5月20日收盘,康泰生物报收于19.9元,上涨0.2%,换手率1.02%,成交量8.95万手,成交额1.78亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052000015559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0201","300601"],"gpt_icon":0},{"id":"2435256689","title":"5月15日康泰生物发生3笔大宗交易 成交金额1929.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435256689","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435256689?lang=zh_cn&edition=full","pubTime":"2024-05-15 16:40","pubTimestamp":1715762446,"startTime":"0","endTime":"0","summary":"证券之星消息,5月15日康泰生物发生大宗交易,交易数据如下:近三个月该股共发生6笔大宗交易,合计成交1.55万手。该股近期无解禁股上市。截至2024年5月15日收盘,康泰生物(300601)报收于19.72元,下跌3.14%,换手率1.1%,成交量9.68万手,成交额1.93亿元。该股最近90天内共有9家机构给出评级,买入评级9家;过去90天内机构目标均价为30.66。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500029429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0239","BK0046"],"gpt_icon":0},{"id":"2433445809","title":"5月6日康泰生物涨5.20%,嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433445809","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433445809?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:38","pubTimestamp":1714984715,"startTime":"0","endTime":"0","summary":"证券之星消息,5月6日康泰生物涨5.20%,收盘报21.25元,换手率2.19%,成交量19.28万手,成交额4.07亿元。重仓康泰生物的前十大公募基金请见下表:该股最近90天内共有7家机构给出评级,买入评级7家。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为3.67亿元,最新净值0.6771,较上一交易日下跌0.15%,近一年下跌25.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600015298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","159646","BK0239","BK0201","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦101","stockEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":-0.0802},{"period":"3month","weight":-0.2323},{"period":"6month","weight":-0.348},{"period":"1year","weight":-0.3972},{"period":"ytd","weight":-0.4232}],"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","perCapita":"13341股","boardName":"医药制造业","registeredCapital":"111691万元","compareEarnings":[{"period":"1week","weight":0.008},{"period":"1month","weight":-0.0176},{"period":"3month","weight":-0.0362},{"period":"6month","weight":0.0461},{"period":"1year","weight":-0.0735},{"period":"ytd","weight":-0.0041}],"survey":" 深圳康泰生物制品股份有限公司主营业务为人用疫苗的研发、生产和销售。公司的主要产品为免疫规划疫苗、非免疫规划疫苗。公司拥有专利70余项,已上市及获批紧急使用的产品10种,在研品种30余项,基本涵盖全球重磅疫苗品种,其中,公司自主研发的用于乙肝疫苗无应答特殊人群的“60µg重组乙型肝炎疫苗(酿酒酵母)”和“双载体13价肺炎球菌多糖结合疫苗”属全球首创。","serverTime":1721245811730,"listedPrice":3.29,"stockholders":"66057人(较上一季度减少1.43%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}